Skip to main content
Chinese Medical Journal logoLink to Chinese Medical Journal
letter
. 2022 Mar 8;135(21):2623–2624. doi: 10.1097/CM9.0000000000002047

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study

Yuankai Sun 1, Jiajia Wang 1, Yulu Qiu 1, Shiyu Lin 1, Fang Wang 2, Wenfeng Tan 1
Editor: Lishao Guo
PMCID: PMC9945485  PMID: 36583925

To the Editor: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease.[1] The hallmark of ankylosing spondylitis (AS) phenotype is sacroiliac joint and spinal damage characterized by the new bone formation and joint fusion, which results in irreversible functional disability and reduced quality of life.

Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug for axSpA patients. Failed to NSAIDs therapy, tumor necrosis factor (TNF)-α inhibitor (TNFi) was suggested in the treatment strategy of axSpA.[2] But 30% of axSpA patients still do not respond or respond inadequately to the TNFi therapy. Moreover, TNF-α antagonists are believed to have a weak effect on preventing osteophyte formation and spinal structure damage in axSpA.

With the increasing understanding of the molecular mechanisms of SpA, interleukin (IL)-17-mediated inflammation not only participates in enthesitis, synovial inflammation, and joint erosion but also contributes to the pathological new bone formation, highlighting the critical role of IL-17 in the pathogenesis of axSpA.[3]

Secukinumab is the first biological agent that targets IL-17. Evidence from the MEASURE study has confirmed the efficacy of secukinumab in SpA.[4]

To estimate the efficacy and tolerance data about secukinumab on Chinese axSpA patients in the routine daily practice, we evaluated the effectiveness, safety, and drug survival in 42 patients with secukinumab therapy at First Affiliated Hospital of Nanjing Medical University from April 2020 to April 2021. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University Hospital (No. 2019-SR-322). Informed consent was obtained from each study participant. All patients met 2009 Assessment Spondylo Arthritis international Society (ASAS) axSpA criteria but failed to respond to NSAIDs and/or TNFi therapy.

Wilcoxon test or analysis of variance was performed to compare the mean values in AS disease activity score with C-reactive protein (ASDAS-CRP), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) at week 0, week 12, and week 24 time point. Drug retention was assessed using Kaplan–Meier curves. All analyses used P < 0.05 for statistical significance.

Among the total of 42 patients, all of them completed 12 weeks of secukinumab treatment and 28, 22, and 18 patients have completed 24 weeks, 36 weeks, and 48 weeks of treatment, respectively.

The mean ASDAS-CRP score at baseline (WK0, n = 42) was 3.1 ± 0.6. At WK12 (n = 42) and WK24 (n = 28) were 2.2 ± 0.6 and 2.2 ± 0.4, receptively. Patients treated with secukinumab experienced significant reductions in ASDAS-CRP scores between WK0 and WK12 (P < 0.0001) and WK24 (P < 0.0001) [Supplementary Figure 1A].

Secukinumab treatment significantly decreased CRP and ESR levels. CRP level decreased from 30.7 ± 35.2 mg/L at WK0 to 7.9 ± 9.4 mg/L at WK12 (P < 0.0001 vs. WK0), and to 6.4 ± 4.7 mg/L at WK24 (P < 0.0001 vs. WK0). A similar reduction trend was also observed in serum ESR levels. ESR decreased from 38.0 ± 26.8 mm/h at baseline to 15.9 ± 12.6 mm/h at WK12 (P < 0.0001 vs. WK0) and 12.1 ± 10.8 mm/h at WK24 (P < 0.0001 vs. WK0) [Supplementary Figure 1B and C].

A total of 18 patients failed to respond to previous TNFi therapy in this study. The efficacy of secukinumab was also analyzed on these TNFi non-responders. ASDAS-CRP, CRP, and ESR also reduced significantly in these patients. ASDAS-CRP decreased from 3.3 ± 0.7 (n = 18) at WK0 to 2.1 ± 0.5 at WK12 (P < 0.0001 vs. WK0), and to 2.1 ± 0.4 at WK24 (n = 13) (P = 0.0012 vs. WK0) [Supplementary Figure 1D].

Secukinumab was well tolerated. Only six (14.3%) adverse events (AEs) were reported in 42 patients that consisted of three upper respiratory infections, one urticarial symptom, one rash, and one abdominal discomfort. None of the serious AEs was reported in these patients. Only one patient discontinued secukinumab therapy due to AEs (recurrent rashes). Among the 42 patients, 35 (83.4%) patients were satisfied with the therapeutic effect of secukinumab, and 3 (7.1%) patients claimed the common efficacy of secukinumab when compared with other medications they have used. Four (9.5%) patients thought secukinumab failed to meet their needs [Supplementary Figure 1E].

In the present study, axSpA patients had a high persistence rate for secukinumab therapy. Among these 42 patients who enrolled from April 2020 to April 2021, all patients have completed 12 weeks of secukinumab therapy, 28 patients have completed 24 weeks, and 18 patients have completed 48 weeks. The crude drug survival was 95.2%, 92.9%, and 76.2% at WK12, WK24, and WK48, respectively [Supplementary Figure 1F]. Four patients (9.5%) discontinued the drug for reasons of lack of efficacy; the remaining patients (14.3%, n = 6) discontinued treatment for multiple reasons: one patient (2.4%) for frequent AEs (rash), one patient (2.4%) for financial burden, two patients (4.8%) for clinical remission, and two patients (4.8%) decided to stop injection because of worrying about the side effects of long-term injection therapy.

The present study shows that the IL-17 inhibitor secukinumab is effective and safe in the treatment of axSpA in daily clinical practice. The past 12 weeks and 24 weeks of secukinumab therapy witnessed that ASDAS-CRP was markedly reduced in these patients. Furthermore, secukinumab was generally well tolerated with a high drug retention rate.

The current study evaluated the effectiveness of secukinumab in the treatment of axSpA in a real-life clinical setting in Chinese patients. Results from this study indicate that secukinumab treatment is effective in improving disease activity including ASDAS-CRP scores over a 12-week to 24-week observation period. There was consistent remission in ESR and CRP over time of secukinumab treatment. Only one patient discontinued secukinumab therapy due to AEs in the current study. The incidence of AEs was comparable with that in the previous clinical trials. No additional or unexpected safety signals were observed.

This study had several limitations. Unable to retrospect other disease activity scores (including Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index data), we cannot evaluate the concrete time at which patients achieved ASAS20 or ASAS40 standard. Given secukinumab was proved to treat patients with AS for only about 1 year in China, the small sample size and the limited follow-up period were not enough to conclude efficacy and safety in axSpA patients.

To conclude, the current results suggest that secukinumab is effective and generally safe in the treatment of active axSpA in daily clinical practice in Chinese patients.

Acknowledgments

The authors thank the patients who participated in the study, the study investigators.

Funding

This work was supported by grants from the National Natural Science Foundation of China (Nos. 81971532, 81971533), and the clinical research incubation program of Jiangsu Province Hospital.

Conflicts of interest

None.

Supplementary Material

Supplemental Digital Content
cm9-135-2623-s001.doc (88.5KB, doc)

Footnotes

How to cite this article: Sun Y, Wang J, Qiu Y, Lin S, Wang F, Tan W. Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study. Chin Med J 2022;135:2623–2624. doi: 10.1097/CM9.0000000000002047

Supplemental digital content is available for this article.

References

  • 1.Weisman MH. Inflammatory back pain: the United States perspective. Rheum Dis Clin North Am 2012; 38:501–512. doi: 10.1016/j.rdc.2012.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (London, England) 2002; 359:1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  • 3.Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21:719–729. doi: 10.1038/nm.3895. [DOI] [PubMed] [Google Scholar]
  • 4.Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017; 76:1070–1077. doi: 10.1136/annrheumdis-2016-209730. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Digital Content
cm9-135-2623-s001.doc (88.5KB, doc)

Articles from Chinese Medical Journal are provided here courtesy of Wolters Kluwer Health

RESOURCES